Inhibitor Therapeutics INTI
OTC INTI
$0.10 +0.00 (+0.00%)
At close: Sep 29, 2026 · 4:00 PM EDT

Inhibitor Therapeutics (INTI) Other Operating Expenses (2012 - 2020)

Updated

Inhibitor Therapeutics (INTI) posted Other Operating Expenses of $14.25 million for FY2023, up 12.9% from $12.62 million in FY2022.

Analysis

Inhibitor Therapeutics (INTI) Other Operating Expenses (2012 - 2020) Analysis & Trends

Since FY2013, Inhibitor Therapeutics has reported Other Operating Expenses for 4 years.

  • Business Quant data shows INTI's Other Operating Expenses at $12.62 million in FY2022 and -$10.00 in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Inhibitor Therapeutics 17.38 Mn 17.38 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 -10.00
Jun 30, 2013 117,324.00
Dec 31, 2012 -31,625.00
API Access

Inhibitor Therapeutics Other Operating Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-operating-expenses&ticker=INTI&period=max&api_key=YOUR_API_KEY